Orchestra BioMed Holdings, Inc.
HealthcareNASDAQ:OBIO · NASDAQ Global Market
+$0.03 today
Vol 0.54M · Avg 0.21M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-83.2%
avg -54.7%
ROIC
-52.4%
avg -165.4%
ROA
-45.9%
avg -73.2%
Analysis
ROA is currently the strongest return metric at -45.9% versus its period average of -73.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David Hochman | Founder, Chairman of the Board of Directors & Chief Executive Officer | $1.18M | — | 51 | $436,199.00 | 0.73% |
Darren R. Sherman | Founder, President, Chief Operating Officer & Director | $1.04M | — | 55 | $1.18M | 1.98% |
Andrew Lawrence Taylor | Chief Financial Officer | $766,677.00 | — | 55 | $593,065.00 | 0.99% |
Yuval Hay Mika D.Sc | GM & Chief Technology Officer of Bioelectronic Therapies | — | — | 67 | $158,905.00 | 0.27% |
Bob Laughner | Senior Vice President of Regulatory & Quality | — | — | — | — | — |
William Reed Little | Executive Vice President of Corporate Development & Strategy | — | — | 55 | $307,859.00 | 0.51% |
Avraham Matityahu Fischer | Senior Vice President of Medical Affairs & Innovation | — | — | 70 | — | — |
Hans-Peter Stoll | Senior Vice President & Medical Director | — | — | — | — | — |
Juan Lorenzo | Senior Vice President of Product Development | — | — | — | — | — |
Lisa Daniels | Vice President of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
16
$2.25M
Sells
3
$66,365.31
Net Sentiment
+$2.18M
Net buying
Most Active
Hochman David P
6 transactions
1–10 of 19
Analysis
Insiders reported 16 buys worth $2.25M and 3 sells worth $66,365.31 over the last 12 months. That adds up to net buying of $2.18M. Hochman David P was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +86.6% (6yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Forward estimates point to Revenue at +86.6% (6yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Prelude Therapeutics Incorporated
NASDAQ:PRLD
$352.45M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$276.28M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$202.22M
Inventiva S.A.
NASDAQ:IVA
$200.13M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$166.70M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$118.59M
Pyxis Oncology, Inc.
NASDAQ:PYXS
$111.51M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Who manages OBIO?
Orchestra BioMed Holdings, Inc. (OBIO) lists 10 active executives. The top listed executive is Yuval Hay Mika D.Sc, GM & Chief Technology Officer of Bioelectronic Therapies.
Are OBIO insiders buying or selling?
Recent insider activity shows net buying of $23.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.